Biofarm, one of the most important Romanian manufacturers of medicines and food supplements, recorded a turnover of 263.2 million RON in the first nine months of 2025, 14 percent above the level of the same period in 2024, while EBITDA increased by 16 percent, reaching 109 million RON.

“The results confirm our sustainable growth strategy, based on portfolio consolidation and continuous investment in innovation and quality. In a complex market environment, we maintain a healthy pace of development, driven mainly by the performance of our established brands and operational discipline. We remain focused on expanding our Consumer Healthcare portfolio and adapting quickly to consumer needs,” said Cătălin Vicol, General Manager of Biofarm. 

Biofarm operates two pharmaceutical production facilities in Bucharest and a testing and product development unit. Its portfolio of over 100 products covers the most important therapeutic areas within the Consumer Healthcare division (digestive & metabolic, respiratory & ORL, cardiovascular & circulatory, and nervous system).